ATE194769T1 - Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen - Google Patents

Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen

Info

Publication number
ATE194769T1
ATE194769T1 AT94930608T AT94930608T ATE194769T1 AT E194769 T1 ATE194769 T1 AT E194769T1 AT 94930608 T AT94930608 T AT 94930608T AT 94930608 T AT94930608 T AT 94930608T AT E194769 T1 ATE194769 T1 AT E194769T1
Authority
AT
Austria
Prior art keywords
cells
hypoxic cells
nitrogen oxide
medicinal agents
releasing compounds
Prior art date
Application number
AT94930608T
Other languages
English (en)
Inventor
James B Mitchell
Angelo Russo
Murali C Krishna
David A Wink Jr
James E Liebmann
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE194769T1 publication Critical patent/ATE194769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT94930608T 1993-10-08 1994-10-07 Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen ATE194769T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13357493A 1993-10-08 1993-10-08
PCT/US1994/011306 WO1995010267A1 (en) 1993-10-08 1994-10-07 Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers

Publications (1)

Publication Number Publication Date
ATE194769T1 true ATE194769T1 (de) 2000-08-15

Family

ID=22459281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930608T ATE194769T1 (de) 1993-10-08 1994-10-07 Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen

Country Status (7)

Country Link
US (3) US5650442A (de)
EP (1) EP0722320B1 (de)
AT (1) ATE194769T1 (de)
AU (1) AU685178B2 (de)
CA (1) CA2173738A1 (de)
DE (1) DE69425331D1 (de)
WO (1) WO1995010267A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5691423A (en) * 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5840759A (en) * 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
CA2173738A1 (en) * 1993-10-08 1995-04-20 James B. Mitchell Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
AU3986097A (en) * 1996-08-27 1998-03-19 University Of Akron, The Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
WO1999009912A1 (en) * 1997-08-26 1999-03-04 Technion Research And Development Foundation Ltd. Intravascular apparatus and method
US6159143A (en) * 1998-06-17 2000-12-12 Scimed Life Systems, Inc. Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
ES2232613T3 (es) * 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6270779B1 (en) * 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
WO2004026111A2 (en) 2000-11-16 2004-04-01 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US6514193B2 (en) 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
WO2003026717A1 (en) * 2001-09-26 2003-04-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
EP1465634B1 (de) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Verfahren zur verwendung adenosinrezeptorinhibitoren zur verstärkung der immunantwort und entzündung
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7531133B2 (en) 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US8501858B2 (en) * 2002-09-12 2013-08-06 Board Of Trustees Of Michigan State University Expanded graphite and products produced therefrom
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP1590440A4 (de) * 2003-02-03 2009-03-18 Palo Alto Inst Of Molecular Me Zellabtötende moleküle und vefahren zu deren verwendung
JP5564158B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
JP4738352B2 (ja) * 2004-02-09 2011-08-03 アミュレット ファーマシューティカルズ インコーポレイティッド 一酸化窒素放出ポリマー
US20080029093A1 (en) * 2004-05-11 2008-02-07 Alex Stenzler Intermittent Dosing Of Nitric Oxide Gas
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
KR20070045187A (ko) * 2004-06-10 2007-05-02 고쿠리츠다이가쿠호진 도호쿠다이가쿠 항암제의 효과 증강제
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (de) 2005-05-27 2013-01-16 Univ North Carolina Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
US20080241208A1 (en) * 2005-06-30 2008-10-02 Charles Shanley Methods, Compositions and Devices For Promoting Anglogenesis
EP1896091B1 (de) * 2005-06-30 2011-06-22 Accord Biomaterials, Inc. Stickstoffoxidbeschichtungen für medizinische vorrichtungen
WO2007005759A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Analyte sensors and compositions for use therein
US8187159B2 (en) 2005-07-22 2012-05-29 Biocompatibles, UK Therapeutic member including a rail used in brachytherapy and other radiation therapy
US7736293B2 (en) * 2005-07-22 2010-06-15 Biocompatibles Uk Limited Implants for use in brachytherapy and other radiation therapy that resist migration and rotation
US20070116785A1 (en) * 2005-11-18 2007-05-24 Miller Christopher C Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
JP2009518069A (ja) * 2005-12-02 2009-05-07 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 組成物、コーティング及びデバイス、並びにそれらの製造方法及び使用方法
EP1968615A4 (de) * 2005-12-06 2010-08-04 Amulet Pharmaceuticals Inc Stickoxid freisetzende polymere
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
EP2237788A4 (de) * 2007-12-27 2013-06-05 Aires Pharmaceuticals Inc Aerosolisierte nitrit- und stickoxidspendende verbindungen und ihre verwendung
AU2009279676C1 (en) * 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
EP2517736B1 (de) 2009-02-23 2014-03-26 Noxilizer, Inc. Vorrichtung zur Gassterilisation
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2588465B1 (de) 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9199026B2 (en) * 2011-01-07 2015-12-01 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
CN106117194A (zh) 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
CA2897426A1 (en) 2012-01-09 2013-07-18 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (de) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc-stimulatoren
EA033168B1 (ru) 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
CA2933250A1 (en) 2013-12-11 2015-06-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP3094327A1 (de) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen
EP3194382B1 (de) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazolderivate als sgc-stimulatoren
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194386A2 (de) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
EA039683B1 (ru) 2016-07-07 2022-02-28 Сайклерион Терапьютикс, Инк. ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
CN109563087A (zh) 2016-07-07 2019-04-02 铁木医药有限公司 sGC刺激剂的固体形式
EP3523367A4 (de) 2016-10-07 2020-06-03 The University Of North Carolina At Chapel Hill S-nitrosothiol-vermittelte hyperverzweigte polyester
US11072668B2 (en) 2017-01-03 2021-07-27 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7403152B2 (ja) 2017-03-28 2023-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景
AU2018369760B2 (en) 2017-11-15 2025-01-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7645546B2 (ja) 2018-12-28 2025-03-14 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法
CN113975388A (zh) * 2021-09-27 2022-01-28 深圳市人民医院 一种聚多巴胺修饰黑磷纳米复合材料和制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
WO1992018112A1 (en) * 1991-04-19 1992-10-29 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
WO1993007114A1 (en) * 1991-09-24 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
WO1993020806A1 (en) * 1992-04-13 1993-10-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide/nucleophile complexes for the treatment of cancer
CA2173738A1 (en) * 1993-10-08 1995-04-20 James B. Mitchell Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers

Also Published As

Publication number Publication date
CA2173738A1 (en) 1995-04-20
AU685178B2 (en) 1998-01-15
EP0722320B1 (de) 2000-07-19
US5814667A (en) 1998-09-29
DE69425331D1 (de) 2000-08-24
WO1995010267A1 (en) 1995-04-20
US5650442A (en) 1997-07-22
US5837736A (en) 1998-11-17
AU7967394A (en) 1995-05-04
EP0722320A1 (de) 1996-07-24

Similar Documents

Publication Publication Date Title
ATE194769T1 (de) Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
DK0649658T3 (da) Anvendelse af 1,2,4-benzotriazinoxider til fremstilling af et lægemiddel til behandling af tumorer
D'Angio et al. Potentiation of x-ray effects by actinomycin D
ATE192922T1 (de) Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ATE174894T1 (de) Analoge von acylfulven als antitumormittel
RU2002115864A (ru) Лечение злокачественных опухолей аплидином
Coldiron Recalcitrant onychomycosis of the toenails successfully treated with fluconazole
ES2134778T3 (es) Bistriazenos como agentes quimioterapeuticos.
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
ATE240100T1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
Rojas et al. Experimental radiotherapy with WR-2721 and misonidazole
Bhardwaj et al. An intensive sequenced adjuvant chemotherapy regimen for breast cancer
Antoku et al. Combined Effects of Radiosensitizers and Radioprotectors on Cultured Mammalian Cells to Co-60 γ-Rays
Laster et al. In vivo studies in NCT with a boronated porphyrin and tumor growth delay as an end point
CN110496136A (zh) 锂制剂在制备治疗或预防癌症药物中的应用
Wickstrom Chlorambucil inhibition by dimethyl sulfoxide and thiosulfate: implications for chlorambucil chemotherapy
CN119972200A (zh) 电离辐射提高铜离子催化点击反应活性的方法及应用
Ptasiewicz-Bak et al. Crystal chemistry of coordination compounds with heterocyclic ligands. Part XXXIX: The crystal and molecular structure of a strontium (II) complex with pyrazine-2, 6-dicarboxylate and water ligands
US20050208149A1 (en) Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
Kim et al. Therapeutic Results of Radiation Therapy Alone and Combination with Chemotherapy in Non-Small Cell Lung Carcinoma
Dallacker et al. Combined Action of Thermal Neutron Irradiation and Boron-10-Amino acid Analogs on a Solid Experimental Tumor (EO771 C57 B1/6J) W. Porschen, J. Marx, H. Muhlensiepen, LE Feinendegeu Institute of Medicine, Nuclear Research Center Julich GmbH., D-5170 Julich, Federal Republic of Germany
Chu et al. The treatment of inflammatory breast carcinoma by radiation
Yanagië et al. Targeting of Boronated Anti-Afp MoAB to Hepatoma Cells: Applications of Boronated MoAB for BNCT

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties